Please assess the completion status of the following clinical trial:

Trial Title: Electrochemotherapy as a Palliative Treatment for Brain Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 18 years.~* Performance status \< 2 (ECOG - Eastern Cooperative Oncology Group).~* Diagnosis of brain metastases originated from histological or cytological verified cancer of any histology.~* Patients should have received whole-brain radiation therapy (WBRT) with a time interval of at least 2 months from completion of WBRT until inclusion in this study.~* Patients must have been offered every available standard treatment.~* Brain metastases to be treated must have a diameter of at least 10 millimetres and no more than 27 millimetres.~* Brain metastases to be treated must be accessible for treatment.~* Estimated life expectancy must be more than 3 months.~* Patients must have adequate organ functions:~Adequate bone marrow reserve: Leucocytes (WBC) \> 3.0 x 109/l, thrombocytes \> 75 x 109/l, hemoglobin \> 7 g/dl.~Hepatic: Alkaline phosphate, ALAT or ASAT and bilirubin must not be increased more than 2 times, pp \> 40, APTT in normal range. Medical correction is allowed, e.g. correction of low pp using vitamin K.~Renal: if creatinin \> 150 micromolar do a GFR examination (Chrome-EDTA).~* Patients must not have a blood pressure (BP) over 180 mm Hg systolic and 110 mm Hg diastolic.~* Sexually active men and women of childbearing potential must use adequate birth control during this study and 6 month after the administration of bleomycin (contraceptive pills, intrauterine devices, injection of prolonged gestagen, subdermal implantation, hormonal vaginal devices, transdermal patches).~* Participating patients must be able to understand the patient information.~* Participating patients must have signed a written informed consent and power of attorney prior to inclusion in this study.~Exclusion Criteria:~* Acute lung infection.~* Previous bleomycin treatment with more than 200.000 IU/m2.~* Previous allergic reaction to bleomycin.~* Allergy towards the sedation used.~* Pregnancy or breastfeeding. Pregnancy in fertile women is excluded by a measurement of HCG in a blood sample. Sterile or infertile women are excluded from the requirement to use anticonception. To be considered sterile or infertile, the patient must have undergone surgical sterilization (vasectomy/bilateral tubectomy, hysterectomy and bilateral ovariectomy) or be post-menopausal defined as the absence of menstruation.~* Treatment with G-CSF (Granulocyte Colony Stimulating Factor) or other cytokines.~* Lung diffusion capacity (DLCO) below normal. DLCO is to be performed in case of suspected (anamnestic or clinical) reduced lung function.~* Physician's assessment that meningeal carcinomatosis (leptomeningeal disease) is a likely cause of the patient's symptoms.~* Treatment with anticoagulants (marevan, marcumar, innohep).~* Allergic to nickel, chrome or cobalt.~* Participation in another clinical study with an experimental drug up to 4 weeks prior to inclusion.~* Illnesses, medical, social or physiological, that may affect the patient's ability to understand the patient information and participate in the follow-up.~* Other serious systemic illnesses (i.e. active infection, abnormal EKG) that the investigator finds may affect the patient's safety and/or ability to complete the study.~* Treatment with Immunosuppressant drugs such as methotrexate and cyclosporine during the study. Treatment with prednisolone is accepted during the study.~* Implanted pacemaker, defibrillators or hearth valve prosthetics.~* Implanted devices such as neurostimulators, eartransplants, insulinpump, metallic tracheostomy.~* Catheters with metal such as Port á cath, Swan Ganz, P-dialysis cath., ventriculoatrial and -peritoneal shunts, bladder cath. with thermo-measurement.~* Metallic clips/prosthetics/magnets from surgery such as neuro- or abdominal clips, tooth- or other prosthetics.~* Disorganised metallic material such as metal fragments in the eyes, shrapnel, gun shot injuries.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues